Veterinary Pain Management Global Market Report 2023 – By Product (Drugs, Devices), By Animal Type (Companion Animals, Livestock), By Distribution Channel (Hospitals and Clinics, Pharmacy), By Application (Joint Pain, Postoperative Pain, Cancer, Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

The term veterinary anti-infective refers to a broad category where animals are cared for by providing both illness prevention and cure approaches. The main types of drugs classes in veterinary anti-infectives are antimicrobial agents, antiviral agents, antifungal agents, and others. Antimicrobial agents are natural or synthetic substances that work by killing or inhibiting the growth of microorganisms such as bacteria, fungi, and algae. The various species types involved are livestock animals and companion animals that are administered through oral, parenteral, and topical modes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, and other distribution channels. The global veterinary anti-infectives market is segmented – 1) By Drug Class: Antimicrobial Agents, Antiviral Agents, Antifungal Agents, Other Drug Classes 2) By Species Type: Livestock Animals, Companion Animals 3) By Mode Of Administration: Oral, Parenteral, Topical 4) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies, Others Distribution Channels The global veterinary anti-infectives market size will grow from $4.64 billion in 2022 to $5.08 billion in 2023 at a compound annual growth rate (CAGR) of 9.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of veterinary anti-infectives is expected to grow to $7 billion in 2027 at a CAGR of 8.3%. An increase in pet ownership is expected to propel the growth of the veterinary anti-infectives market going forward. Pet ownership refers to owning a dog, cat, or other domestic pet at home. Pet are being adopted as increasing number of the young population are considering them as part of their family, some owners are adopting them for their compassion, loyalty and the to prevent loneliness. For instance, according to South China Morning Post, a Hong Kong-based English-language newspaper, pet owners in China have reached 62.94 million in 2020 – up from 62.8 million in 2019. Therefore, an increase in pet ownership is driving the demand for veterinary anti-infectives market. Major players in the veterinary anti-infectives market are Bayer AG, Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health Incorporated, Zoetis Inc., Vetoquinol, Merck & Co., Phibro Animal Health, Aspen Veterinary Resources Ltd., Bimeda Animal Health Limited, Dechra Pharmaceuticals, Intervet International B.V., Oceanic Pharmachem, Virbac Ltd., Indian Immunologicals Ltd (IIL), Norbrook Laboratories, and Ashish Life Science. Technological advancements are a key trend gaining popularity in the veterinary anti-infectives market. Major companies operating in the market are using advanced technologies to sustain their position in the veterinary anti-infectives market. For instance, in February 2021, Elanco Animal Health Incorporated, a US-based pharmaceutical company that manufactures drugs and vaccinations for pets and livestock launched Increxxa, the newly approved drug for livestock respiratory disease. Increxxa with its key ingredient being tulathromycin is delivered to the livestock in injection and targets the lungs' site of infection swiftly for fast action and a lengthy half-life, providing cattle more time to establish a strong defense. This product is designed for veterinary use and tulathromycin, the active ingredient in Increxxa, helps decrease the negative effects of bovine respiratory disease. In June 2022, Ceva Santé Animale, a France-based multinational animal health company, acquired Artemis Technologies, Inc for an undisclosed amount. This acquisition complements Ceva's rabies portfolio and extensive knowledge of the development of oral rabies vaccines and campaign management in Europe and other regions. Ceva will increase its market footprint in North America with this acquisition. Artemis Technologies, Inc is a Canada-based oral rabies vaccine manufacturer. North America was the largest region in the veterinary anti-infectives market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary anti-infectives market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary anti-infectives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The veterinary anti-infectives market consists of revenues earned by entities by providing antibacterial that are used to prevent and treat animal diseases such as infections. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary anti-infectives market research report is one of a series of new reports from The Business Research Company that provides veterinary anti-infectives market statistics, including veterinary anti-infectives industry global market size, regional shares, competitors with veterinary anti-infectives market share, detailed veterinary anti-infectives market segments, market trends, and opportunities, and any further data you may need to thrive in the veterinary anti-infectives industry. This veterinary anti-infectives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The veterinary infectious disease diagnostics refer to diagnostic services that are used for the identification of infectious diseases in animals. These are the sets of infectious diseases and the factors that impact the health of livestock, domestic animals, and wildlife. Veterinary diagnostics has become essential to ensure the overall well-being of animals. These diagnose the infections caused in all types of animals. The main types of veterinary infectious disease diagnostics are viral infections, bacterial infections, parasitic infections, and other infections. Bacterial infections are transmitted from dogs to humans by a dog bite. However, other infections caused by protozoa have a fecal-oral transmission. The different animals include companion animals, food-producing animals, and involve various technologies such as immunodiagnostics, molecular diagnostics, and other technologies. These are used in reference laboratories, veterinary hospitals and clinics, point of care, research institutes and universities, and other end users. The global veterinary infectious disease diagnostics market is segmented - 1) By Infection Type: Viral Infections, Bacterial Infections, Parasitic Infections, Other Infections 2) By Animal Type: Companion Animal, Food-Producing animals 3) By Technology: Immunodiagnostics, Molecular Diagnostic, Other Technologies 4) By End User: Reference Laboratories, Veterinary Hospitals and Clinics, Point of Care, Research Institutes and Universities, Other End Users The global veterinary infectious disease diagnostics market size will grow from $1.65 billion in 2022 to $1.85 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of veterinary infectious disease diagnostics market is expected to grow to $2.74 billion in 2027 at a CAGR of 10.4%. The increasing incidence of transboundary and zoonotic diseases such as rabies is expected to propel the growth of the veterinary infectious disease diagnostics market going forward. Zoonoses are diseases and infections that are transferred spontaneously between humans and vertebrate animals. Veterinary infectious disease diagnostics are used to detect rabies in pets and animals. These devices are used to prevent animals from causing death. For instance, in 2021, according to the World Health Organization (WHO), a Swiss-based government agency, rabies disease was found in over 150 nations and territories. Dogs are the most common source of human rabies deaths, accounting for up to 99% of all rabies transmissions. Children under the age of 15 make up 40% of those bitten by suspected rabid animals. Infection kills tens of thousands of people every year, mostly in Asia and Africa. Therefore, the increasing incidence of transboundary and zoonotic diseases is driving the growth of the veterinary infectious disease diagnostics market. Major players in the veterinary infectious disease diagnostics market are Zoetis Inc., IDEXX Laboratories Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., IDvet, NEOGEN Corporation, INDICAL BIOSCIENCE GmbH, Randox Laboratories Ltd., Creative Diagnostics, Heska Corporation, Chembio Diagnostics, URIT Medical Electronic Co. Ltd., NTBIO Diagnostics Inc., Bio-X Diagnostics, and Agrolabo Spa. Technological advancements have emerged as the key trend gaining popularity in the veterinary infectious disease diagnostics market. Major companies operating in the veterinary infectious disease diagnostics market are introducing new technological innovations to sustain their position in the market. For instance, in 2020, LexaGene, a US-based company operating in veterinary infectious disease diagnostics, released MiQLab, a gold standard diagnostic equipment that uses a unique RT-qPCR-based technology to evaluate each sample's contents for up to 27 distinct pathogens in under an hour. MiQLab is unique in that it is open-source, allowing users to customize existing tests and build new ones with ease. If a new test is necessary due to a mutation, the open-access functionality allows new tests to be developed quickly on LexaGene's MiQLab system. In January 2020, Heska Corp., a US-based company that manufactures point-of-care diagnostics equipment and imaging devices, acquired Scil Animal Care Co. for a deal amount of $110 million. With this acquisition, Heska Corp.'s overseas market share increased to 40% in Germany and 30% in Spain and France, which also expanded the company's animal care offering. Social Animal Care is a France based company that manufactures veterinary diagnostic devices. North America was the largest region in the veterinary disease diagnostics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary infectious disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary infectious disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The veterinary infectious disease diagnostics market includes revenues earned by entities by identifying and determining whether an animal has any viral, bacterial, parasitic, or other types of illnesses. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary infectious disease diagnostics market research report is one of a series of new reports from The Business Research Company that provides veterinary infectious disease diagnostics market statistics, including veterinary infectious disease diagnostics industry global market size, regional shares, competitors with a veterinary infectious disease diagnostics market share, detailed veterinary infectious disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary infectious disease diagnostics industry. This veterinary infectious disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The animal antibiotics and antimicrobials refer to veterinary medications that work against bacteria or microorganisms by either killing bacteria/microorganisms or limiting their development and multiplication. These medications are used in animals to treat clinical diseases, to prevent or control common disease events, and enhance animal growth. The main types of animal antibiotics and antimicrobials include tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobials and antibiotics. Tetracyclines are bacteriostatic, and their mechanism of action is through reversible binding of bacterial 30S ribosomes and alteration of bacterial cytoplasmic membrane. They are also referred to as oral medication used in treatment of bacterial infections due to aerobic, gram-negative bacteria, mycoplasma, and others. These are delivered in different forms including premixes, oral powder, oral solutions, injection, and others. These medications are used in both companion and food-producing animals. The global animal antibiotics and antimicrobials market is segmented – 1) By Type of Product: Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Cephalosporins, Other Antimicrobials and Antibiotics 2) By Mode of Delivery: Premixes, Oral Powder, Oral Solution, Injection, Other Modes of Delivery 3) By Animal Type: Food-Producing Animals, Companion Animals The global animal antibiotics and antimicrobials market size will grow from $4.68 billion in 2022 to $5.07 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of animal antibiotics and antimicrobials market is expected to grow to $6.95 billion in 2027 at a CAGR of 8.2%. Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market. Animal-derived food products such as milk, eggs, meat, and other act a major source of nutrition and plays a prominent role in human diet. The companies/institutions involved in production of animal-derived foods are focusing on developing healthy herd or disease-free herd through utilization of animal antibiotics and antimicrobials on precautionary basis. According to the data published in the Packaged Facts report on Global Meat & Poultry trends, global meat and poultry consumption is expected to reach 313 million metric tons in 2023, at a year-on-year growth rate of 1.4%. Therefore, increasing demand for animal-derived food products is expected to boost demand for animal antibiotics and antimicrobials during forecast period. Major players in the animal antibiotics and antimicrobials market are Boehringer Ingelheim, Zoetis Inc., Elanco Animal Health, Merck & Co. Inc., Phibro Animal Health, Vetoquinol SA, Lutim Pharma, Ceva Santé Animale, Dechra Pharmaceuticals PLC., Kyoritsu Seiyaku, Huvepharma Inc., Zydus, Indian Immunologicals Pvt. Ltd., Bayer Animal Health, Virbac Animal Health, and Phibro Animal Health Corp. Strategic partnership is a key trend gaining popularity in the animal antibiotics and antimicrobials market. The companies operating in animal antibiotics and antimicrobial sector are entering into strategic partnerships with relevant industry players for the research and development of innovative animal antibiotics and antimicrobials. In May 2022, Gnubiotics Sciences, a Switzerland-based biotech company working to solve microbiome-related health conditions in humans and animals, entered into a partnership with ADM, a US-based developer of human and health nutrition solutions, for commercializing new microbiome solutions for companion animal health and wellbeing. In August 2020, Elanco, a US-based pharmaceutical company that manufacturers medicines and vaccinations for pets and livestock, acquired Bayer’s animal health business unit for $6.89 billion. With this acquisition, Elanco will improve its research and development pipeline and broaden its range of animal health products. Bayer’s animal health business unit is a Germany-based pharmaceutical and life sciences company. North America was the largest region in the animal antibiotics and antimicrobials market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal antibiotics and antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal antibiotics and antimicrobials market consists of sales of glycopeptides, ß-Lactam antibiotics, and polymixins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal antibiotics and antimicrobials market research report is one of a series of new reports from The Business Research Company that provides animal antibiotics and antimicrobials market statistics, including animal antibiotics and antimicrobials industry global market size, regional shares, competitors with a animal antibiotics and antimicrobials market share, detailed animal antibiotics and antimicrobials market segments, market trends and opportunities, and any further data you may need to thrive in the animal antibiotics and antimicrobials industry. This animal antibiotics and antimicrobials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Veterinary antibiotics refer to a class of animal medications that are used to treat infectious disease in animals by killing microorganisms such as bacteria and parasites by inhibiting the growth of their cell walls to fight infections and diseases in animals caused by bacteria and improve the animals' health conditions. The main product types of veterinary antibiotics include anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drugs, and other products. Non-steroidal anti-inflammatory drugs (NSAIDs) act as a bridge between the production and activity of prostaglandins (enzymes) implicated in inflammation. Approved veterinary NSAIDs are used in companion animal care to reduce the pain and swelling linked with osteoarthritis in dogs and horses. The administration of veterinary antibiotics includes premixes, injections, oral powders, oral solutions, and other administrations used on farm animals and companion animals. The global veterinary antibiotics market is segmented - 1) By Product: Anti-Parasitic, Anti-Bacterial, Non-Steroidal Anti-Inflammatory Drug, Other Products 2) By End User: Farm Animals, Companion Animals 3) By Administration: Premixes, Injections, Oral Powders, Oral Solutions, Other Administration The global veterinary antibiotics market size will grow from $1.86 billion in 2022 to $2.02 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global veterinary antibiotics is expected to grow to $2.7 billion in 2027 at a CAGR of 7.5%. An increase in the number of zoonotic diseases is driving the veterinary antibiotics market. Zoonotic diseases are infectious diseases caused by microscopic organisms, infections, and parasites that spread between animals and humans. Two of the most common zoonotic pathogens, salmonella and campylobacter, are present in the intestines of these animals. Zoonotic diseases are also a potential threat to humans as they get transferred through the food chain. A study conducted by the FoodNet (Centers for Disease Control and Prevention, USA) found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused by zoonotic diseases. In addition, the highest incidences per 100,000 people in the USA are caused by infectious diseases such as campylobacter, salmonella, and shigella. Therefore, there is a need to diagnose these diseases in animals at an early stage, which is a major driver of the veterinary antibiotics market. Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, CevaSanteAnimale, Eli Lilly Company, ElanCo., Merck & Co., Sanofi, Virbac, Zoetis, and Crystal Pharma. The rising threat of antibiotic resistance is a major restraint for the veterinary antibiotics market. Antibiotic resistance in animals refers to the ability of a microbe to withstand the impact of an antibiotic that once successfully treated infections caused by the same type of microbe. This can be a result of using antibiotics more than the prescribed limit. In this regard, the European Union (EU) has approved various restrictions on veterinary antibiotics, including a ban on antibiotics for animals and prohibiting the usage of antimicrobials in food, which is restricting the veterinary antibiotics market growth. Increasing collaboration between companies is an emerging trend in the veterinary antibiotics market. Collaboration offers companies the opportunity to combine technologies and a wide range, more diversified products to work with, and it also improves the quality of the antibiotics and the speed at which they are produced. Therefore, companies in the veterinary antibiotics market are focusing on collaborations. For instance, in September 2022, GlobalVetLink, a US-based provider of software services and informatics solutions in the field of animals, collaborated with Veterinary Innovative Partners to install GlobalVetLink Compliance Assistant, a thorough SaaS platform developed to simplify animal health. The veterinary antibiotics prescription drugs market is regulated by Section 503(f) of the Food, Drug, and Cosmetic Act of FDA. According to this law, the veterinary antibiotic drug labels are mandated to include a caution statement that states that these drugs can only be used with the permission of a licenced veterinarian. The sale and use of antibiotic prescription drugs without a prescription is usually reported to the FDA and strict action is taken based on it. Hence, regulations such as these would regulate veterinary antibiotic manufacturers and sellers. North America was the largest region in the veterinary antibiotics market in 2022. Asia-Pacific was the second-largest region in the global veterinary antibiotics market share. The regions covered in the global veterinary antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary antibiotics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary antibiotics market consists of sales of antivirals, antiprotozoals, antifungals, aminoglycosides, beta-lactams, fluoroquinolones, glycopeptides, and lipopeptides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary antibiotics research report is one of a series of new reports from The Business Research Company that provides veterinary antibiotics statistics, including veterinary antibiotics industry global market size, regional shares, competitors with veterinary antibiotics share, detailed veterinary antibiotics segments, market trends and opportunities, and any further data you may need to thrive in the veterinary antibiotics industry. The veterinary antibiotics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Veterinary pharmaceuticals are a class of drugs that are pharmacologically active and used to control, prevent, and treat diseases in animals. They have an effect when administered to animals and are rapidly broken down into active ingredients due to small intestine metabolism. The main types of veterinary pharmaceuticals include veterinary vaccines, veterinary antibiotics, veterinary parasiticides, and other types. Veterinary vaccines provide protection against one or more diseases, which can lower the severity or prevent certain diseases entirely. The routes of administration include oral and other routes of administration for animal types, including companion animals and livestock animals. The vaccines include inactivated vaccines, attenuated vaccines, and recombinant vaccines. The global veterinary pharmaceuticals market is segmented - 1) By Type: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Types 2) By End User: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores 3) By Route of Administration: Oral, Other Routes Of Administration 4) By Animal Type: Companion Animals, Livestock Animals 5) By Vaccines: Inactivated Vaccines, Attenuated Vaccines, Recombinant Vaccines The global veterinary pharmaceuticals market size will grow from $28.43 billion in 2022 to $30.2 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the veterinary pharmaceuticals is expected to grow from $37.12 billion in 2027 at a CAGR of 5.3%. Major players in the veterinary pharmaceuticals market are Merck & Co. Inc., Zoetis Inc., Eli Lilly and Company, Bayer AG, Boehringer Ingelheim GmbH, Perrigo Company PLC., Virbac SA, Dechra Pharmaceuticals PLC., CevaSanteAnimale, and Aratana Therapeutics. The increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary pharmaceuticals market. The increase in the incidence of diseases in livestock and companion animals will require medicines to treat the animals for the diseases. For instance, according to the Banfield State of Pet Health Report, the prevalence of diabetes in dogs has increased by 79.7% from 13.1 cases per 10,000 to 23.6 cases whereas the prevalence rate increased by 18% in cats. The increase in the prevalence rate of diseases among animals results in an increased demand for veterinary pharmaceuticals market. The veterinary pharmaceuticals market is being restrained by a lack of awareness about animal healthcare. According to the Animal Welfare Act 2006, proper healthcare means the pet should have regular vaccinations, a suitable diet, protection from pain and suffering, suffering and should be free from any kind of disease. According to the PDSA Animal Wellbeing (PAW) UK report, only 38% of people in the UK are aware of this legislation which shows a very less proportion of the population is aware of animal healthcare and acts as a major restraint for the veterinary pharmaceuticals market. The rise of generic drugs for animal care is being seen as the latest trend in the veterinary pharmaceuticals market. The economical nature of generic drugs enables pet lovers to take care of their pets efficiently. The FDA has approved 22 generic animal drugs for cats and dogs, which has increased the adoption of generic drugs by veterinarians. According to a survey conducted on 520 veterinarians by Brakke and Trone Brand Energy Inc., around 80% of the veterinarians confirmed that they are using generic drugs to save the pet owners’ money. However, the lower margin of profit given by generic drug manufacturers compared with the heavy margins of branded drugs needs to be looked into by veterinarians. The veterinary pharmaceuticals market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US Food and Drug Administration), and others. For instance, the EU agencies require 6 to 12 months to approve veterinary medicinal products. Moreover, it requires all parts of the registration dossier to be submitted together, unlike the US-FDA, which accepts phased submissions. The US-FDA assesses each technical section for 6 months which may be extended to another 6 month cycle if questions or concerns are raised. However, the technical sections’ assessment is done simultaneously, and therefore, the manufacturers should identify the time-consuming steps and plan the work accordingly and estimate the date of approval. Also, the license validity and renewal of the application in the EU region is very difficult upon the existing regulatory policies. Therefore, the manufacturers of veterinary pharmaceuticals should plan well, communicate effectively to minimize the costs and reduce timelines. North America was the largest region in the veterinary pharmaceuticals market in 2022. Asia-Pacific was the second-largest region in the global veterinary pharmaceuticals market report. The regions covered in the global veterinary pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary pharmaceuticals market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The veterinary pharmaceuticals market consists of sales of biological drugs, biosimilars, monoclonal antibodies, sedatives, and antihistaminic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary pharmaceuticals research report is one of a series of new reports from The Business Research Company that provides veterinary pharmaceuticals statistics, including veterinary pharmaceuticals industry global market size, regional shares, competitors with veterinary pharmaceuticals share, detailed veterinary pharmaceuticals segments, market trends and opportunities, and any further data you may need to thrive in the veterinary pharmaceuticals industry. This veterinary pharmaceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary vaccine refers to a biological preparation that stimulates the immune response of an animal against disease in order to reduce animal suffering and the transmission of microorganisms in the animal population and enhance the immunity power of animals by improving animal health, which also prevents the transmission of diseases from animals to humans. The various types of veterinary vaccines are live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine types. Inactivated vaccines differ from live but attenuated vaccines as they are made up of dead, or inactivated, viruses and bacteria. The disease types are anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, and porcine reproductive and respiratory syndrome, and the application areas include livestock vaccines, and companion animal vaccines. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccine Types 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot And Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive And Respiratory Syndrome (PRRS) The global veterinary vaccines market size will grow from $10.89 billion in 2022 to $11.57 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global veterinary vaccines is expected to grow to $14.2 billion in 2027 at a CAGR of 5.3%. The increase in the number of animals suffering from a range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from a report by the Animal and Plant Health Agency, a total of 3289 new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals, causing a general state of illness, coughing and eventually leading to death. However, the disease can be treated with specific antibiotics that kill the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. Major players in the veterinary vaccines market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), CevaSantéAnimale, Virbac, Biovac, Zoetis Animal Healthcare, and Hester Biosciences Ltd. High storage costs are acting as a major restraint on the growth of the veterinary vaccine market. Improper storage conditions and delays in shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines to maintain their efficiency, which increases the storage and transportation costs for the vaccines. According to a report published by the National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potency during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the veterinary vaccines market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share research and development projects. For example, in 2020, the Pirbright Institute, a UK-based animal disease research institute, partnered with ECO Animal Health, a UK-based pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK. Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to the vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also, Wageningen bio veterinary research made a strategic alliance with Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as the European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, of Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety tests before getting approval, where vaccines are classified into activated vaccines and inactivated vaccines. For inactivated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. North America was the largest region in the veterinary vaccines market in 2022. Asia-Pacific was the second-largest region in the global veterinary vaccines market analysis. The regions covered in the global veterinary vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary vaccines market consists of sales of messenger RNA vaccine, viral vector vaccine, and subunit vaccine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides veterinary vaccines statistics, including veterinary vaccines industry global market size, regional shares, competitors with veterinary vaccines share, detailed veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the veterinary vaccines industry. The veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The probiotics in the animal feed refer to a live microbial feed additive that enhances the intestinal balance of the host animal. Probiotics are widely employed in animal feeding and are regarded as growth and health stimulators. Most probiotics used in animal nutrition are generated commercially and sold in liquid and solid forms. The main forms of probiotics in animal feed are dry and liquid. The dry probiotics are used in the animal feed in the form of dried powder form, tablets, and capsules. Dry probiotics come in a variety of shapes and sizes and are made using a freeze-drying method. The various sources of probiotics in animal feed include bacteria and yeast and fungi. They are used in feed of cattle, poultry, swine, aquaculture, and other applications. The global probiotics in animal feed market is segmented - 1) By Form Type: Dry, Liquid 2) By Source Type: Bacteria, Yeast and Fungi 3) By Application Type: Cattle, Poultry, Swine, Aquaculture, Other Applications The global probiotics in animal feed market size grew from $4.26 billion in 2022 to $4.62 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of the global probiotics in animal feed is expected to grow to $6.35 billion in 2027 at a CAGR of 8.2%. The growing demand for eggs and poultry meat contributes to the growth of probiotics in the animal feed market. The demand for eggs and poultry meat is increasing because of the rise in population, greater purchasing power, and urbanization. Moreover, increasing awareness about the nutrients and protein from eggs and meat are contributing towards their demand. Probiotics are used as an additive in the poultry feed, which keeps the poultry farm animals disease-free and boosts their immunity to produce more eggs and meat. For instance, in 2020, according to the Food and Agricultural Organisation of the United Nations, the global production of poultry meat increased from 9 to 133 million tonnes, and egg production increased from 15 to 93 million tonnes between 1961 and 2020. Poultry meat accounted for 40% of the total meat produced worldwide in 2020. Egg production increased by 150% in the last three decades. Thus, increased demand for eggs and poultry meat is expected to boost the demand for probiotics in the animal feed during the forecast period. Major players in the probiotics in animal feed market report are Chr. Hansen, Koninklijke DSM N.V., DuPont, Evonik Industries, Land O'Lakes, Calpis Co., Ltd., Ohly, Lesaffre, Alltech, Novozymes, Unique Biotech, Archer Daniels Midland Company (ADM), Advance aqua bio technologies, Danisco A/S, and Kerry Group. Partnerships and collaborations is a key trend gaining popularity in the probiotics in the animal feed market. The companies operating in the probiotics in the animal feed market are focusing on establishing partnership with relevent technology companies to expand their product development activities and enhance their market reach. For instance, in September 2020, Proteon Pharmaceuticals, a Poland-based biotechnology company, partnered with DuPont Animal Nutrition. The partnership aims to use DuPont's reputable and trusted brand to help poultry producers in particular nations access Proteon's bacteriophage technology. In addition to improving Proteon's distribution capabilities and strengthening DuPont's product line, the partnership will help further reduce antimicrobial resistance (AMR) in farm animals. DuPont Animal Nutrition is a biotechnology research company that produces a wide range of feed enzymes, betaine, phytogenics, and probiotics. In January 2021, Novozymes, a Denmark-based biotechnology company specializing in research, development, and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients, acquired Microbiome Labs for $125 million. Through this acquisition, Novozymes will focus on probiotics for human use as a growth area. It offers the chance to advance our work in human health, expand its portfolio, and cement its leadership in the North American probiotics market. Microbiome Labs is an Illinois-based company that focuses on providing probiotic bacterio therapy. Asia-Pacific was the largest region in the probiotics in animal feed market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global probiotics in animal feed market share during the forecast period. The regions covered in the probiotics in animal feed market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the probiotics in animal feed market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The prebiotics in the amimal feed market consists of sales of lactobacillus, bacillus, streptococcus, pediococcus, enterococcus, bifidobacterium, and propionibacterium. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The probiotics in animal feed market research report are one of a series of new reports from The Business Research Company that provides probiotics in animal feed market statistics, including probiotics in animal feed industry global market size, regional shares, competitors with market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the probiotics in the animal feed industry. This probiotics in animal feed market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary healthcare refers to a healthcare service that is associated with the diagnosis, treatment, and prevention of diseases in animals and the duties of an individual whose job it is to provide medical care for animals who are ill or injured, or to describe such care to reduce transmission of infectious disease from one pet to another. The main types of veterinary healthcare are veterinary services, veterinary medical equipment, animal medicine and are used for the animals such as dogs and cats, horses, ruminants, swine, poultry, and other animals. Veterinary services refer to the healthcare services that are provided to the animals. The products include instruments/equipment, disposables. The global veterinary healthcare market is segmented - 1) By Type: Veterinary Services, Veterinary Medical Equipment, Animal Medicine 2) By Product: Instruments/Equipment, Disposables 3) By Animal Type: Dogs and Cats, Horses, Ruminants, Swine, Poultry, Other Animals Subsegments Covered: Animal Hospitals And Veterinary Clinics, Veterinary Laboratory Testing Services, Veterinary Diagnostic Equipment, Veterinary Anesthesia Equipment, Veterinary Patient Monitoring Equipment, Other Veterinary Medical Equipment, Veterinary Pharmaceuticals, Feed Additives The global veterinary healthcare market size will grow from $180.32 billion in 2022 to $195.77 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of veterinary healthcare is expected to grow from $261.48 billion in 2027 at a CAGR of 7.5%. Global meat production is expected to rise in the forecast period, supporting the growth of the veterinary healthcare market. According to the US Department of Agriculture, in 2020, the beef production in the USA reached27.5 billion pounds, the highest production volume registered in the country. Rising meat production is especially prominent in developing countries such as China, India, and Brazil, where increasing populations and rising income levels are stimulating the demand for meat products. By 2027, the production of meat and poultry in emerging markets is expected to increase by 76%. By 2050, China's meat imports are expected to grow by over 3,500% to $150 billion as consumption of chicken, pork, and beef will surge due to the country's rising middle class. The rising production of meat products supported by the growing population will increase the demand for feed additives in the livestock industry, driving the veterinary healthcare market. Major companies in the veterinary healthcare market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co, IDEXX Laboratories, Evonik Industries AG, Patterson Companies Inc., Ceva Animal Health LLC – Biomune; Pets at Home Group PLC, National Veterinary Associates, and Phirbo Animal Health. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the veterinary healthcare market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the veterinary healthcare market will recover from the shock over the forecast period as it is a 'black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute for veterinary antibiotics to tackle antibiotic resistance. Nanotechnology is the study of controlling matter on an atomic and molecular scale. In the animal medicine industry is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccine candidates to improve their characteristics and performance, and to reduce drug resistance in animal organisms. North America was the largest region in the veterinary healthcare market in 2022. Asia-Pacific was the second-largest region in the veterinary healthcare market. The regions covered in the veterinary healthcare report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary healthcare market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The veterinary healthcare market includes revenues earned by entities by providing treatment for diseases that influence the health of domestic and wild animals and must be prevented, controlled, diagnosed, and treated, along with the human transmission of animal diseases.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary healthcare research report is one of a series of new reports from The Business Research Company that provides veterinary healthcare statistics, including veterinary healthcare industry global market size, regional shares, competitors with veterinary healthcare share, detailed veterinary healthcare segments, market trends and opportunities, and any further data you may need to thrive in the veterinary healthcare industry. This veterinary healthcare research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.